apixaban
Eliquis
Pharmaceutical company: Bristol-Myers Squibb Company and Pfizer Inc.
NEW FORM:
Capsule for oral suspension: 0.15 mg
Tablet for oral suspension: 0.5 mg
NEW INDICATION & DOSAGE
Treatment of VTE and reduction in risk of recurrent VTE after at least 5 days of initial anticoagulant treatment
Children weighing 35 kg or more: 10 mg PO b.i.d. days 1 to 7, then 5 mg b.i.d.
Children weighing 25 to less than 35 kg: 8 mg PO b.i.d. days 1 to 7, then 4 mg b.i.d.
Children weighing 18 to less than 25 kg: 6 mg PO b.i.d. days 1 to 7, then 3 mg b.i.d.
Children weighing 12 to less than 18 kg: 4 mg PO b.i.d. days 1 to 7, then 2 mg b.i.d.
Children weighing 9 to less than 12 kg: 3 mg PO b.i.d. days 1 to 7, then 1.5 mg b.i.d.
Children weighing 6 to less than 9 kg: 2 mg PO b.i.d. days 1 to 7, then 1 mg b.i.d.
Children weighing 4 to less than 6 kg: 1 mg PO b.i.d. days 1 to 7, then 0.5 mg b.i.d.
Children weighing 2.6 to less than 4 kg: 0.3 mg PO b.i.d. days 1 to 7, then 0.15 mg b.i.d.
Adjust-a-dose: Individualize therapy duration based on bleeding risk assessment.
Released: June 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
diazepam
Valtoco
Pharmaceutical company: Neurelis, Inc.
NEW INDICATION & DOSAGE
Acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from usual seizure pattern in patients with epilepsy (intranasal)
Children ages 2 to 5 weighing 23 to 33 kg: 7.5 mg intranasally in both nostrils (15 mg total).
Children ages 2 to 5 weighing 12 to 22 kg: 10mg intranasally in one nostril (10 mg total).
Children ages 2 to 5 weighing 6 to 11 kg: 5 mg intranasally in one nostril (5 mg total).
Adjust-a-dose: If a second dose is needed, give at least 4 hours after initial dose. Don't use more than two doses to treat a single episode.
Released: June 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
palbociclib
Ibrance
Pharmaceutical company: Pfizer, Inc.
NEW INDICATION & DOSAGE
Endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with inavolisib and fulvestrant following recurrence on or after completing adjuvant endocrine therapy
Adult males or adult females who are postmenopausal: 125 mg PO daily for 21 consecutive days followed by 7 days off to complete a cycle of 28 days. Treat patients who are premenopausal and perimenopausal with a luteinizing hormone-releasing hormone (LHRH) agonist according to current standards. Male patients should be considered for treatment with an LHRH agonist according to current standards. See manufacturer's instructions for inavolisib and fulvestrant dosing information.
Adjust-a-dose: For patients with Child-Pugh class C liver impairment, decrease dosage to 75 mg PO daily. If concomitant use of strong CYP3A inhibitors is unavoidable, decrease palbociclib dosage to 75 mg daily. If strong inhibitor is discontinued, increase palbociclib dosage after three to five half-lives have passed from CYP3A inhibitor dose. See manufacturer's instructions.
Released: June 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
tedizolid
Sivextro
Pharmaceutical company: Merck & Co., Inc.
NEW INDICATION & DOSAGE
Acute bacterial skin and skin-structure infections caused by susceptible gram-positive isolates (Staphylococcus aureus [including MRSA and methicillin-susceptible strains], Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group [including S. anginosus, S. intermedius, and S. constellatus], and Enterococcus faecalis)
Children weighing 35 kg or more: 200 mg PO or IV daily for 6 days.
Children at least 26 weeks gestation weighing 20 to less than 35 kg: 60-mg IV infusion b.i.d. for 6 days.
Children at least 26 weeks gestation weighing 14 to less than 20 kg 40-mg IV infusion b.i.d. for 6 days.
Children at least 26 weeks gestation weighing 10 to less than 14 kg: 30-mg IV infusion b.i.d. for 6 days.
Children at least 26 weeks gestation weighing 6 to less than 10 kg: 20-mg IV infusions b.i.d. for 6 days.
Children at least 26 weeks gestation weighing 3 to less than 6 kg: 12-mg IV infusion b.i.d. for 6 days.
Children at least 26 weeks gestation weighing 2 to less than 3 kg: 6-mg IV infusion b.i.d. for 6 days.
Children at least 26 weeks gestation weighing 1 to less than 2 kg: 3-mg/kg IV infusion b.i.d. for 6 days.
Released: June 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.